Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

NCT06961331 · clinicaltrials.gov ↗

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic HER2+ Advanced Breast Cancer

Interventions

DRUG: Tucatinib
DRUG: Trastuzumab
DRUG: Capecitabine

Sponsor

Pfizer